ContractRevenue Interest Assignment Agreement • May 5th, 2020 • New York
EX-10.3 4 pdli-201593010qex103.htm REVENUE INTEREST ASSIGNMENT AGREEMENT Exhibit 10.3 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* * *” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. REVENUE INTEREST ASSIGNMENT AGREEMENT Dated as of July 28, 2015 between ARIAD PHARMACEUTICALS, INC. and PDL BIOPHARMA, INC. Table of Contents
REVENUE INTEREST ASSIGNMENT AGREEMENT Dated as of July 28, 2015 between ARIAD PHARMACEUTICALS, INC. and PDL BIOPHARMA, INC. Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and...Revenue Interest Assignment Agreement • November 6th, 2015 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This REVENUE INTEREST ASSIGNMENT AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of July 28, 2015, by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (“ARIAD” or the “Company”), and PDL BioPharma, Inc., a Delaware corporation (“Purchaser”).
EXHIBIT 2.04 REVENUE INTEREST ASSIGNMENT AGREEMENT Dated as of October 28, 2003Revenue Interest Assignment Agreement • November 12th, 2003 • Guilford Pharmaceuticals Inc • Pharmaceutical preparations • New York
